3月13日,白云山披露了2024年年报:去年公司营利双降,营收约749.93亿元,同比下降0.69%;净利润约28.35亿元,同比下降30.09%,创近七年新低。白云山向股东传递的信息是:基本业务面受到严重影响,核心竞争力越来越弱。白云山中药产品下滑了3%;化药产品下滑幅度高达20%;曾经的“抓钱铁手”大健康板块也下滑了13%,表明“王老吉”也不如以往。曾经是白云山“最硬的品种”、辉瑞“万艾可”的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.